Latest Headlines

  1. Medtronic Options QT Vascular’s Chocolate PTA Balloon Catheter
    5/11/2017

    QT Vascular Ltd., (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today that it has entered into an asset purchase option agreement ("Option Agreement") with Medtronic, for the acquisition of the Group's non-drug coated Chocolate® PTA.

  2. Siemens Healthineers, Imricor Team On Integrated Solution To Treat Arrhythmia
    5/10/2017

    Siemens Healthineers is joining forces with U.S.-based Imricor Medical Systems Inc. to develop an integrated solution that combines the clinical benefits of real-time MRI scans with 3D-guided cardiac ablation.

  3. Medtronic’s Quadripolar CRT-Ps Gain FDA Approval
    5/10/2017

    Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps) that improve therapy delivery for patients with heart failure.

  4. Boston Scientific’s Resonate ICDs, CRT-Ds Gain FDA Approval
    5/9/2017

    Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems.

  5. BD, UniteOR Collaborate On Integrated Tracking Solution For Operating Rooms
    5/9/2017

    BD (Becton, Dickinson and Company), a leading global medical technology company and UniteOR, Inc., announced recently the integration between BD’s IMPRESS instrument management system and UniteOR’s cloud-based surgical tray tracking and vendor management solution, that enables greater visibility of surgical tray management to health care workers in the operating room and sterile processing department.

  6. Abbott’s Sensor-Enabled Ablation Catheter Gains CE Mark Approval
    5/9/2017

    Abbott (NYSE: ABT) today announced CE Mark of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, developed to make it easier for physicians to more effectively treat atrial fibrillation (AF), a condition in which the upper chambers of the heart beat too fast.

  7. Cardiff Intl. To Acquire Prostate Dx Device Maker MedicaMetrix
    5/9/2017

    Cardiff International, Inc. (OTCQB: CDIF) and MedicaMetrix®, Inc. (Private; "MedicaMetrix") announced today they have signed a Letter of Intent agreement under which MedicaMetrix will merge into Cardiff International as its subsidiary, MedicaMetrix, Inc., in an all-stock transaction valued at approximately $6 million. 

  8. Outsourced Pharma Announces San Diego Forum Agenda Following Successful Boston Event
    5/8/2017

    Outsourced Pharma announced the agenda for its San Diego event at the conclusion of its Boston conference held this past April. An Early Start on Drug Development and Manufacturing Outsourcing is scheduled for August 22-23 at the Hyatt Regency La Jolla. The complete agenda and list of panelists can be found here.

  9. Abbott Wins CE Mark For First Smartphone-Compatible Insertable Cardiac Monitor
    5/8/2017

    Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm Rx™ Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy.

  10. Systemic Therapy Outperforms Intraocular Implant For Treating Uveitis
    5/8/2017

    Systemic therapy consisting of corticosteroids and immunosuppressants preserved vision of uveitis patients better — and had fewer adverse outcomes — than a long-lasting corticosteroid intraocular implant, according to a clinical trial funded by the National Eye Institute (NEI).